Ionis製藥 IONS 深 滬
等待開盤 11-08 09:30:00 美东时间
73.19
-0.910
-1.23%
華盛通- 最 高75.00
- 今 開73.79
- 成交量 127.53万股
- 最 低 72.36
- 昨 收 74.10
- 總市值 116.37亿
- 52周最高 76.78
- 市盈率 靜 --
- 換手率 0.80%
- 52周最低 23.95
- 委 比 -4.27%
- 總股本 1.59亿
- 歷史最高 86.582
- 量 比 0.71
- 振 幅 3.56%
- 歷史最低 6.25
- 每 手 1
- 風險率 13.24%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Ionis Pharmaceuticals Releases Long-Term Data For Dawnzera Showing Durable Efficacy And Safety
DAWNZERA showed durable efficacy, demonstrating 94% overall mean HAE attack rate reduction at one year in OASISplus open-label extension studyPatients in OASISplus switch study achieved 68% improvement in mean HAE attack
11-06 21:19
美股大行评级 | 最高255美元！9家大行集体上调Palantir目标价；Axsome、Exact、Fabrinet、ZoomInfo、爱德士、MongoDB、安森美半导体等也获多家大行上调目标价
今日重点评级关注：瑞银：维持Syndax Pharmaceuticals"买入"评级，目标价从35美元升至38美元；HC Wainwright & Co.：维持Benitec Biopharma"买入"评级，目标价从28美元升至35美元
11-05 10:35
Preview: Exelixis's Earnings
Exelixis (NASDAQ:EXEL) is set to give its latest quarterly earnings report on T...
11-03 23:03
Earnings Preview: Exact Sciences
Exact Sciences (NASDAQ:EXAS) is gearing up to announce its quarterly earnings o...
10-31 23:01
美股大行评级 | 最高350美元！16家大行上调谷歌目标价！Meta遭12家大行下调目标价；潜在涨幅1456.29%！NRX Pharmaceuticals获Ascendiant Capital升目标价至47美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持NRX Pharmaceuticals"买入"评级，目标价从46美元升至47美元；富国银行：维持Kyverna Therapeutics"超配"评级，目标价从27美元升至31美元
10-31 10:25
GigaMedia Announces Third-Quarter 2025 Financial Results
TAIPEI, Oct. 30, 2025 /PRNewswire/ -- GigaMedia Limited (NASDAQ: GIGM) today announced its third-quarter 2025 unaudited financial results. Comments from Management In the third quarter of 20...
10-30 21:00
Needham Maintains Buy on Ionis Pharmaceuticals, Raises Price Target to $90
Needham analyst Joseph Stringer maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and raises the price target from $78 to $90.
10-30 18:19
Humacyte Announces Publication of New Data Comparing Symvess™ to Autologous Vein in Extremity Arterial Trauma
Humacyte announced the publication of a study comparing Symvess to autologous vein in treating extremity arterial trauma. Results showed similar short-term outcomes in patency, limb salvage, and infection rates. Symvess achieved comparable primary patency (86.6% vs. 91.8%), secondary patency (91.0% vs. 97.7%), amputation rate (7.5% vs. 8.2%), and death rate (4.5% vs. 4.5%). While autologous vein is the current gold standard, Symvess offers a viab...
10-30 12:00
康菲中国总裁胡凯诚荣获中国政府友谊奖
北京2025年10月30日 /美通社/ -- 康菲石油中国有限公司（"康菲中国"）总裁胡凯诚（Markel Hübinette）先生荣获2025年度中国政府友谊...
10-30 11:12
PIZZA HUT CELEBRATES "HALLO-WINGS" BY SCARING THE COMPETITION
Pizza Hut Haunts Wingstop by Deploying a Fleet of Out-of-Home Locations at Wingstop Headquarters and Stores Designed to Remind the World Pizza Hut is an Authority in Both Pizza and Wings PLA...
10-30 02:54
